Arcus Biosciences (RCUS) 44th Annual J.P. Morgan Healthcare Conference summary

Company Overview and Strategy

• Focused on late-stage oncology and emerging immunology, leveraging strong medicinal chemistry and discovery capabilities.

• Maintains aggressive research and clinical trial activity, supported by strategic partnerships and a robust cash position extending into the second half of 2028.

• Portfolio includes wholly owned, best-in-class molecules, with casdatifan as the lead asset targeting HIF-2α in kidney cancer.

• Emphasizes strategic optionality and independence, with a shift toward clinical collaborations that add value to internal programs.

• Partnerships with AstraZeneca, Taiho Pharma, and Gilead have enabled capital efficiency and risk sharing.

Clinical Development Highlights

• Casdatifan, a HIF-2α inhibitor, demonstrated median PFS over 12 months in late-line RCC, outperforming benchmarks like Merck’s belzutifan.

• PEAK-1 Phase III trial for casdatifan plus cabozantinib in post-IO ccRCC is enrolling, with full enrollment targeted in under 18 months.

• Multiple first-line, TKI-free regimens for casdatifan in RCC are being evaluated, with a Phase III study planned by year-end 2026.

• Quemliclustat in front-line pancreatic cancer shows median OS of 16 months versus 9–11 months for standard care; PRISM-1 trial fully enrolled, readout expected in H1 2027.

• Near-term focus is on clear cell RCC, with potential expansion to other indications like liver cancer in the future.

Immunology and Inflammation Pipeline

• Immunology pipeline includes MRGPRX2 antagonist for atopic skin diseases and selective TNF receptor 1 inhibitor, both aiming for clinical entry by 2026–2027.

• Immunology programs target validated pathways with large commercial potential, leveraging small molecule expertise for differentiated oral therapies.

• Additional programs in CCR6 and CD40L are in advanced discovery stages.